Thyroid eye disease: Pathogenesis and treatment

Ophthalmologica

Volumn 224, Issue 4, 2010, Pages 199-203

  Sikder, Shameema ^a   Weinberg, Robert S ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Graves' disease; Graves' ophthalmopathy; Thyroid eye disease

Indexed keywords

CORTICOSTEROID; CYCLOOXYGENASE 2; DICLOFENAC; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RITUXIMAB; ROSIGLITAZONE; STEROID;

AUTOIMMUNITY; B LYMPHOCYTE; CELL ACTIVATION; CLINICAL FEATURE; DISEASE CLASSIFICATION; DRUG EFFICACY; ENDOCRINE OPHTHALMOPATHY; HUMAN; INCIDENCE; MONOCYTE; PATHOGENESIS; PROTEIN EXPRESSION; REVIEW; COMPLICATION; EYE DISEASES; PATHOLOGY; THYROID DISEASES;

EYE DISEASES; HUMANS; THYROID DISEASES;

EID: 70450159858     PISSN: 00303755     EISSN: None     Source Type: Journal    
DOI: 10.1159/000260224     Document Type: Review

References (23)

1. Bartley GB: The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota. Trans Am Ophthalmol Soc 1994; 92: 477-588.
2. Werner SC: Modification of the classification of the eye changes of Graves' disease: recommendations of the Ad Hoc Committee of the American Thyroid Association. J Clin Endocrinol Metab 1977; 44: 203-204.
3. Werner SC: Classification of thyroid disease: report of the Committee on Nomenclature. The American Thyroid Association. J Clin Endocrinol Metab 1969; 29: 860-862.
4. Molnár I: The balance shift in Th1/Th2 related IL-12/IL-5 cytokines in Graves' disease during methimazole therapy. Autoimmunity 2007; 40: 31-37.
5. Weetman AP: Hyperthyroidism and Graves' disease; in Besser GM, Thorner MO (eds): Comprehensive Clinical Endocrinology, ed 3. Edinburgh, Mosby, 2002, pp 165-180.
6. Durairaj VD: Clinical perspectives of thyroid eye disease. Am J Med 2006; 119: 1027-1028.
7. Mourits MP, Prummel MF, Wiersinga WM, Koornneef L: Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy. Clin Endocrinol 1997; 47: 9-14.
8. Gerding MN, Prummel MF, Wiersinga WM: Assessment of disease activity in Graves' ophthalmopathy by orbital ultrasonography and clinical parameters. Clin Endocrinol 2000; 52: 641-646.
9. Bartley GB, Fatourechi V, Kadrmas EF, Jacobsen SJ, Ilstrup DM, Garrity JA, Gorman CA: Chronology of Graves' ophthalmopathy in an incidence cohort. Am J Ophthalmol 1996; 121: 426-443.
10. Bahn RS, Dutton CM, Natt N, Joba W, Spitzweg C, Heufelder AE: Thyrotropin receptor expression in Graves' orbital adipose-connective tissues: potential autoantigen in Graves' ophthalmopathy. J Clin Endocrinol Metab 1998; 83: 998-1002.
11. Khoo TK, Bahn RS: Pathogenesis of Graves' ophthalmopathy: the role of autoantibodies. Thyroid 2007; 17: 1013-1018.
12. Huber AK, Jacobson EM, Jazdzewski K, Concepcion ES, Tomer Y: IL-23R is a major susceptibility gene for Graves' ophthalmopathy: the IL-23/Th17 axis extends to thyroid autoimmunity. J Clin Endocrinol Metab 2007; 93: 1077-1081.
13. Lacka K, Manuszewska E, Korczowska I, Lacki JK: The effect of methylprednisolone pulse treatment on cytokine network in Graves' ophthalmopathy. Curr Eye Res 2007; 32: 291-297.
14. Konuk EB, Konuk O, Misirlioglu M, Menevse A, Unal M: Expression of cyclooxygenase-2 in orbital fibroadipose connective tissues of Graves' ophthalmopathy patients. Eur J Endocrinol 2006; 155: 681-685.
15. Quadbeck B, Stucke M, Eckstein AK, Heise DJ, Mann K, Gieseler RK: Dysregulation of TNF/TNFR superfamily members: a systemic link between intra-and extrathyroidal manifestations in Graves' disease. Scand J Immunol 2006; 64: 523-530.
16. Wiersinga WM: Management of Graves' ophthalmopathy. Nat Clin Pract Endocrinol Metab 2007; 3: 396-404.
17. Kahaly GJ, Pitz S, Hommel G, Dittmar M: Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves' orbitopathy. J Clin Endocrinol Metab 2005; 90: 5234-5240.
18. Zoumalan CI, Cockerham KP, Turbin RE, Volpe NJ, Kazim M, Douglas RS, Feldon SE: Efficacy of corticosteroids and external beam radiation in the management of moderate to severe thyroid eye disease. J Neuroophthalmol 2007; 27: 205-214.
19. Adamson DJ, Frew D, Tatoud R, Wolf CR, Palmer CN: Diclofenac antagonizes peroxisome proliferator-activated receptor-gamma signaling. Mol Pharmacol 2002; 61: 7-12.
20. Vondrichova T, de Capretz A, Parikh H, Frenander C, Asman P, Aberg M, Groop L, Hallengren B, Lantz M: COX-2 and SCD, markers of inflammation and adipogenesis, are related to disease activity in Graves' ophthalmopathy. Thyroid 2007; 17: 511-517.
21. Nielsen CH, El Fassi D, Hasselbalch HC, Bendtzen K, Hegedüs L: B-cell depletion with rituximab in the treatment of autoimmune diseases: Graves' ophthalmopathy, the latest addition to an expanding family. Expert Opin Biol Ther 2007; 7: 1061-1078.
22. El Fassi D, Nielsen CH, Bonnema SJ, Hasselbalch HC, Hegedüs L: B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot study. J Clin Endocrinol Metab 2007; 92: 1769-1772.
23. Salvi M, Vannucchi G, Campi I, Currò N, Beck-Peccoz P: New immunomodulators in the treatment of Graves' ophthalmopathy. Ann Endocrinol 2008; 69: 153-156.